-
1
-
-
84859847164
-
Emerging insights into the molecular and cellular basis of glioblastoma
-
Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, et al. 2012. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev. 26:756-84
-
(2012)
Genes Dev.
, vol.26
, pp. 756-784
-
-
Dunn, G.P.1
Rinne, M.L.2
Wykosky, J.3
Genovese, G.4
Quayle, S.N.5
-
2
-
-
0035404677
-
Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups
-
Davis FG, Kupelian V, Freels S, McCarthy B, Surawicz T. 2001. Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. Neuro-Oncology 3:152-58
-
(2001)
Neuro-Oncology
, vol.3
, pp. 152-158
-
-
Davis, F.G.1
Kupelian, V.2
Freels, S.3
McCarthy, B.4
Surawicz, T.5
-
3
-
-
84868023931
-
CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2004-2007
-
Dolecek TA, Propp JM, Stroup NE, Kruchko C. 2012. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004-2007. Neuro-Oncology 4 (Suppl. 5):1-49
-
(2012)
Neuro-Oncology
, vol.4
, Issue.SUPPL. 5
, pp. 1-49
-
-
Dolecek, T.A.1
Propp, J.M.2
Stroup, N.E.3
Kruchko, C.4
-
4
-
-
77957067789
-
Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology
-
Porter KR, McCarthy BJ, Freels S, Kim Y, Davis FG. 2010. Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Neuro-Oncology 12:520-27
-
(2010)
Neuro-Oncology
, vol.12
, pp. 520-527
-
-
Porter, K.R.1
McCarthy, B.J.2
Freels, S.3
Kim, Y.4
Davis, F.G.5
-
5
-
-
20344407807
-
Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas
-
Ohgaki H, Kleihues P. 2005. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J. Neuropathol. Exp. Neurol. 64:479-89
-
(2005)
J. Neuropathol. Exp. Neurol.
, vol.64
, pp. 479-489
-
-
Ohgaki, H.1
Kleihues, P.2
-
6
-
-
84860790212
-
Review. Molecular pathology in adult high-grade gliomas: From molecular diagnostics to target therapies
-
Masui K, Cloughesy TF, Mischel PS. 2012. Review. Molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathol. Appl. Neurobiol. 38:271-91
-
(2012)
Neuropathol. Appl. Neurobiol.
, vol.38
, pp. 271-291
-
-
Masui, K.1
Cloughesy, T.F.2
Mischel, P.S.3
-
7
-
-
20044366163
-
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
-
Stupp R, Mason WP, van den Bent MJ, WellerM, Fisher B, et al. 2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352:987-96
-
(2005)
N. Engl. J. Med.
, vol.352
, pp. 987-996
-
-
Stupp, R.1
Mason, W.P.2
Van Den Bent, M.J.3
Weller, M.4
Fisher, B.5
-
8
-
-
84869878282
-
Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice
-
Friedmann-Morvinski D, Bushong EA, Ke E, Soda Y, Marumoto T, et al. 2012. Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science 338:1080-84
-
(2012)
Science
, vol.338
, pp. 1080-1084
-
-
Friedmann-Morvinski, D.1
Bushong, E.A.2
Ke, E.3
Soda, Y.4
Marumoto, T.5
-
9
-
-
34547122001
-
The 2007WHOclassification of tumours of the central nervous system
-
LouisDN, Ohgaki H, Wiestler OD, CaveneeWK, Burger PC, et al. 2007. The 2007WHOclassification of tumours of the central nervous system. Acta Neuropathol. 114:97-109
-
(2007)
Acta Neuropathol.
, vol.114
, pp. 97-109
-
-
Louis, D.N.1
Ohgaki, H.2
Wiestler, O.D.3
Cavenee, W.K.4
Burger, P.C.5
-
10
-
-
84878362165
-
The next step in brain tumor classification "let us now praise famous men" or molecules?
-
Louis DN. 2012. The next step in brain tumor classification: "Let us now praise famous men" or molecules? Acta Neuropathol. 124:761-62
-
(2012)
Acta Neuropathol.
, vol.124
, pp. 761-762
-
-
Louis, D.N.1
-
11
-
-
84874091180
-
The definition of primary and secondary glioblastoma
-
Ohgaki H, Kleihues P. 2013. The definition of primary and secondary glioblastoma. Clin. Cancer Res. 19:764-72
-
(2013)
Clin. Cancer Res.
, vol.19
, pp. 764-772
-
-
Ohgaki, H.1
Kleihues, P.2
-
12
-
-
54549108740
-
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
-
Cancer Genome Atlas Res. Netw.
-
Cancer Genome Atlas Res. Netw. 2008. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-68
-
(2008)
Nature
, vol.455
, pp. 1061-1068
-
-
-
13
-
-
73649123907
-
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1
-
Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, et al. 2010. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110
-
(2010)
Cancer Cell
, vol.17
, pp. 98-110
-
-
Verhaak, R.G.1
Hoadley, K.A.2
Purdom, E.3
Wang, V.4
Qi, Y.5
-
14
-
-
52949127312
-
An integrated genomic analysis of human glioblastoma multiforme
-
Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, et al. 2008. An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-12
-
(2008)
Science
, vol.321
, pp. 1807-1812
-
-
Parsons, D.W.1
Jones, S.2
Zhang, X.3
Lin, J.C.4
Leary, R.J.5
-
15
-
-
38049100456
-
Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma
-
Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, et al. 2007. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc. Natl. Acad. Sci. USA 104:20007-12
-
(2007)
Proc. Natl. Acad. Sci. USA
, vol.104
, pp. 20007-20012
-
-
Beroukhim, R.1
Getz, G.2
Nghiemphu, L.3
Barretina, J.4
Hsueh, T.5
-
16
-
-
79951844223
-
NFKBIA deletion in glioblastomas
-
Bredel M, Scholtens DM, Yadav AK, Alvarez AA, Renfrow JJ, et al. 2011. NFKBIA deletion in glioblastomas. N. Engl. J. Med. 364:627-37
-
(2011)
N. Engl. J. Med.
, vol.364
, pp. 627-637
-
-
Bredel, M.1
Scholtens, D.M.2
Yadav, A.K.3
Alvarez, A.A.4
Renfrow, J.J.5
-
17
-
-
33845926387
-
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain
-
Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, et al. 2006. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. 3:e485
-
(2006)
PLoS Med.
, vol.3
, pp. e485
-
-
Lee, J.C.1
Vivanco, I.2
Beroukhim, R.3
Huang, J.H.4
Feng, W.L.5
-
18
-
-
84874645357
-
Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation
-
Morris LG, Kaufman AM, Gong Y, Ramaswami D, Walsh LA, et al. 2013. Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nat. Genet. 45:253-61
-
(2013)
Nat. Genet.
, vol.45
, pp. 253-261
-
-
Morris, L.G.1
Kaufman, A.M.2
Gong, Y.3
Ramaswami, D.4
Walsh, L.A.5
-
19
-
-
84865805666
-
Transforming fusions of FGFR and TACC genes in human glioblastoma
-
Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, et al. 2012. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 337:1231-35
-
(2012)
Science
, vol.337
, pp. 1231-1235
-
-
Singh, D.1
Chan, J.M.2
Zoppoli, P.3
Niola, F.4
Sullivan, R.5
-
20
-
-
84873347374
-
The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma
-
Parker BC, Annala MJ, Cogdell DE, Granberg KJ, Sun Y, et al. 2013. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J. Clin. Investig. 123:855-65
-
(2013)
J. Clin. Investig.
, vol.123
, pp. 855-865
-
-
Parker, B.C.1
Annala, M.J.2
Cogdell, D.E.3
Granberg, K.J.4
Sun, Y.5
-
21
-
-
33845807801
-
Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities
-
Maher EA, Brennan C, Wen PY, Durso L, Ligon KL, et al. 2006. Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res. 66:11502-13
-
(2006)
Cancer Res.
, vol.66
, pp. 11502-11513
-
-
Maher, E.A.1
Brennan, C.2
Wen, P.Y.3
Durso, L.4
Ligon, K.L.5
-
22
-
-
31544467538
-
Distinct transcription profiles of primary and secondary glioblastoma subgroups
-
Tso CL, Freije WA, Day A, Chen Z, Merriman B, et al. 2006. Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res. 66:159-67
-
(2006)
Cancer Res.
, vol.66
, pp. 159-167
-
-
Tso, C.L.1
Freije, W.A.2
Day, A.3
Chen, Z.4
Merriman, B.5
-
23
-
-
33644820339
-
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis
-
Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, et al. 2006. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157-73
-
(2006)
Cancer Cell
, vol.9
, pp. 157-173
-
-
Phillips, H.S.1
Kharbanda, S.2
Chen, R.3
Forrest, W.F.4
Soriano, R.H.5
-
24
-
-
4644313275
-
Gene expression profiling of gliomas strongly predicts survival
-
Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy TF, et al. 2004. Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 64:6503-10
-
(2004)
Cancer Res.
, vol.64
, pp. 6503-6510
-
-
Freije, W.A.1
Castro-Vargas, F.E.2
Fang, Z.3
Horvath, S.4
Cloughesy, T.F.5
-
25
-
-
77952108366
-
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma
-
Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, et al. 2010. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17:510-22
-
(2010)
Cancer Cell
, vol.17
, pp. 510-522
-
-
Noushmehr, H.1
Weisenberger, D.J.2
Diefes, K.3
Phillips, H.S.4
Pujara, K.5
-
26
-
-
84858796263
-
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
-
Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, et al. 2012. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483:479-83
-
(2012)
Nature
, vol.483
, pp. 479-483
-
-
Turcan, S.1
Rohle, D.2
Goenka, A.3
Walsh, L.A.4
Fang, F.5
-
27
-
-
84862777348
-
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
-
Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, et al. 2012. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482:226-31
-
(2012)
Nature
, vol.482
, pp. 226-231
-
-
Schwartzentruber, J.1
Korshunov, A.2
Liu, X.Y.3
Jones, D.T.4
Pfaff, E.5
-
28
-
-
84867606428
-
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma
-
SturmD, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, et al. 2012. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22:425-37
-
(2012)
Cancer Cell
, vol.22
, pp. 425-437
-
-
Sturm, D.1
Witt, H.2
Hovestadt, V.3
Khuong-Quang, D.A.4
Jones, D.T.5
-
29
-
-
75149195336
-
The transcriptional network for mesenchymal transformation of brain tumours
-
Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, et al. 2010. The transcriptional network for mesenchymal transformation of brain tumours. Nature 463:318-25
-
(2010)
Nature
, vol.463
, pp. 318-325
-
-
Carro, M.S.1
Lim, W.K.2
Alvarez, M.J.3
Bollo, R.J.4
Zhao, X.5
-
30
-
-
80054689794
-
An extensivemicroRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma
-
Sumazin P, Yang X, Chiu HS, Chung WJ, Iyer A, et al. 2011. An extensivemicroRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. Cell 147:370-81
-
(2011)
Cell
, vol.147
, pp. 370-381
-
-
Sumazin, P.1
Yang, X.2
Chiu, H.S.3
Chung, W.J.4
Iyer, A.5
-
31
-
-
84866248155
-
MicroRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma
-
Genovese G, Ergun A, Shukla SA, Campos B, Hanna J, et al. 2012. microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma. Cancer Discov. 2:736-49
-
(2012)
Cancer Discov.
, vol.2
, pp. 736-749
-
-
Genovese, G.1
Ergun, A.2
Shukla, S.A.3
Campos, B.4
Hanna, J.5
-
32
-
-
70849122697
-
Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations
-
Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, et al. 2009. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS ONE 4:e7752
-
(2009)
PLoS ONE
, vol.4
, pp. e7752
-
-
Brennan, C.1
Momota, H.2
Hambardzumyan, D.3
Ozawa, T.4
Tandon, A.5
-
33
-
-
84873336376
-
Multiple functions of a glioblastoma fusion oncogene
-
Babic I, Mischel PS. 2013. Multiple functions of a glioblastoma fusion oncogene. J. Clin. Investig. 123:548-51
-
(2013)
J. Clin. Investig.
, vol.123
, pp. 548-551
-
-
Babic, I.1
Mischel, P.S.2
-
34
-
-
79952509861
-
Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain
-
Chow LM, Endersby R, Zhu X, Rankin S, Qu C, et al. 2011. Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell 19:305-16
-
(2011)
Cancer Cell
, vol.19
, pp. 305-316
-
-
Chow, L.M.1
Endersby, R.2
Zhu, X.3
Rankin, S.4
Qu, C.5
-
35
-
-
38949117993
-
Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples
-
Yoshimoto K, Dang J, Zhu S, NathansonD, Huang T, et al. 2008. Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clin. Cancer Res. 14:488-93
-
(2008)
Clin. Cancer Res.
, vol.14
, pp. 488-493
-
-
Yoshimoto, K.1
Dang, J.2
Zhu, S.3
Nathanson, D.4
Huang, T.5
-
36
-
-
73949083511
-
Oncogenic EGFR signaling networks in glioma
-
Huang PH, Xu AM, White FM. 2009. Oncogenic EGFR signaling networks in glioma. Sci. Signal. 2:re6
-
(2009)
Sci. Signal.
, vol.2
, pp. re6
-
-
Huang, P.H.1
Xu, A.M.2
White, F.M.3
-
37
-
-
84861760527
-
Differential sensitivity of gliomaversus lung cancer-specific EGFR mutations to EGFR kinase inhibitors
-
Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, et al. 2012. Differential sensitivity of gliomaversus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2:458-71
-
(2012)
Cancer Discov.
, vol.2
, pp. 458-471
-
-
Vivanco, I.1
Robins, H.I.2
Rohle, D.3
Campos, C.4
Grommes, C.5
-
38
-
-
77249101567
-
Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence
-
Mukasa A, Wykosky J, Ligon KL, Chin L, Cavenee WK, Furnari F. 2010. Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence. Proc. Natl. Acad. Sci. USA 107:2616-21
-
(2010)
Proc. Natl. Acad. Sci. USA
, vol.107
, pp. 2616-2621
-
-
Mukasa, A.1
Wykosky, J.2
Ligon, K.L.3
Chin, L.4
Cavenee, W.K.5
Furnari, F.6
-
39
-
-
84864400820
-
Phase I/II study of oral erlotinib for treatment of relapsed/refractory glioblastoma multiforme and anaplastic astrocytoma
-
Kesavabhotla K, Schlaff CD, Shin B, Mubita L, Kaplan R, et al. 2012. Phase I/II study of oral erlotinib for treatment of relapsed/refractory glioblastoma multiforme and anaplastic astrocytoma. J. Exp. Ther. Oncol. 10:71-81
-
(2012)
J. Exp. Ther. Oncol.
, vol.10
, pp. 71-81
-
-
Kesavabhotla, K.1
Schlaff, C.D.2
Shin, B.3
Mubita, L.4
Kaplan, R.5
-
40
-
-
78049306732
-
Safety and efficacy of erlotinib in first-relapse glioblastoma: A phase II open-label study
-
Yung WK, Vredenburgh JJ, Cloughesy TF, Nghiemphu P, Klencke B, et al. 2010. Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro-Oncology 12:1061-70
-
(2010)
Neuro-Oncology
, vol.12
, pp. 1061-1070
-
-
Yung, W.K.1
Vredenburgh, J.J.2
Cloughesy, T.F.3
Nghiemphu, P.4
Klencke, B.5
-
41
-
-
75749122223
-
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy
-
Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, et al. 2010. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro-Oncology 12:95-103
-
(2010)
Neuro-Oncology
, vol.12
, pp. 95-103
-
-
Raizer, J.J.1
Abrey, L.E.2
Lassman, A.B.3
Chang, S.M.4
Lamborn, K.R.5
-
42
-
-
34247218483
-
Gefitinib in patients with progressive high-grade gliomas: A multicentre phase II study by Gruppo Italiano Cooperativo di Neuro- Oncologia (GICNO
-
Franceschi E, Cavallo G, Lonardi S, Magrini E, Tosoni A, et al. 2007. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro- Oncologia (GICNO). Br. J. Cancer 96:1047-51
-
(2007)
Br. J. Cancer
, vol.96
, pp. 1047-1051
-
-
Franceschi, E.1
Cavallo, G.2
Lonardi, S.3
Magrini, E.4
Tosoni, A.5
-
43
-
-
62449150719
-
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034
-
van den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MC, Kros JM, et al. 2009. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J. Clin. Oncol. 27:1268-74
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 1268-1274
-
-
Van Den Bent, M.J.1
Brandes, A.A.2
Rampling, R.3
Kouwenhoven, M.C.4
Kros, J.M.5
-
44
-
-
27744606737
-
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
-
Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, et al. 2005. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353:2012-24
-
(2005)
N. Engl. J. Med.
, vol.353
, pp. 2012-2024
-
-
Mellinghoff, I.K.1
Wang, M.Y.2
Vivanco, I.3
Haas-Kogan, D.A.4
Zhu, S.5
-
45
-
-
84865542459
-
Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240
-
Fenton TR, Nathanson D, Ponte de Albuquerque C, Kuga D, Iwanami A, et al. 2012. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. Proc. Natl. Acad. Sci. USA 109:14164-69
-
(2012)
Proc. Natl. Acad. Sci. USA
, vol.109
, pp. 14164-14169
-
-
Fenton, T.R.1
Nathanson, D.2
Ponte De Albuquerque, C.3
Kuga, D.4
Iwanami, A.5
-
46
-
-
77950891445
-
The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation
-
Vivanco I, Rohle D, Versele M, Iwanami A, Kuga D, et al. 2010. The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proc. Natl. Acad. Sci. USA 107:6459-64
-
(2010)
Proc. Natl. Acad. Sci. USA
, vol.107
, pp. 6459-6464
-
-
Vivanco, I.1
Rohle, D.2
Versele, M.3
Iwanami, A.4
Kuga, D.5
-
47
-
-
35348822482
-
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
-
Stommel JM, Kimmelman AC, YingH, Nabioullin R, Ponugoti AH, et al. 2007. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318:287-90
-
(2007)
Science
, vol.318
, pp. 287-290
-
-
Stommel, J.M.1
Kimmelman, A.C.2
Ying, H.3
Nabioullin, R.4
Ponugoti, A.H.5
-
48
-
-
83455176258
-
Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma
-
Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, et al. 2011. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20:810-17
-
(2011)
Cancer Cell
, vol.20
, pp. 810-817
-
-
Snuderl, M.1
Fazlollahi, L.2
Le, L.P.3
Nitta, M.4
Zhelyazkova, B.H.5
-
49
-
-
84857397985
-
Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response
-
Szerlip NJ, Pedraza A, Chakravarty D, Azim M, McGuire J, et al. 2012. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc. Natl. Acad. Sci. USA 109:3041-46
-
(2012)
Proc. Natl. Acad. Sci. USA
, vol.109
, pp. 3041-3046
-
-
Szerlip, N.J.1
Pedraza, A.2
Chakravarty, D.3
Azim, M.4
McGuire, J.5
-
50
-
-
84877593565
-
De-repression ofPDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients
-
AkhavanD, Pourzia AL, Nourian AA, WilliamsKJ, NathansonD, et al. 2013. De-repression ofPDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov. 3:534-47
-
(2013)
Cancer Discov.
, vol.3
, pp. 534-547
-
-
Akhavan, D.1
Pourzia, A.L.2
Nourian, A.A.3
Williams, K.J.4
Nathanson, D.5
-
51
-
-
84861760526
-
Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers
-
Barkovich KJ, Hariono S, Garske AL, Zhang J, Blair JA, et al. 2012. Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers. Cancer Discov. 2:450-57
-
(2012)
Cancer Discov.
, vol.2
, pp. 450-457
-
-
Barkovich, K.J.1
Hariono, S.2
Garske, A.L.3
Zhang, J.4
Blair, J.A.5
-
53
-
-
18244371651
-
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
-
PaoW, Miller VA, Politi KA, Riely GJ, Somwar R, et al. 2005. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2:e73
-
(2005)
PLoS Med.
, vol.2
, pp. e73
-
-
Pao, W.1
Miller, V.A.2
Politi, K.A.3
Riely, G.J.4
Somwar, R.5
-
54
-
-
33745260930
-
AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling
-
Riemenschneider MJ, Betensky RA, Pasedag SM, Louis DN. 2006. AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling. Cancer Res. 66:5618-23
-
(2006)
Cancer Res.
, vol.66
, pp. 5618-5623
-
-
Riemenschneider, M.J.1
Betensky, R.A.2
Pasedag, S.M.3
Louis, D.N.4
-
55
-
-
0038615946
-
Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo
-
Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, et al. 2003. Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 63:2742-46
-
(2003)
Cancer Res.
, vol.63
, pp. 2742-2746
-
-
Choe, G.1
Horvath, S.2
Cloughesy, T.F.3
Crosby, K.4
Seligson, D.5
-
56
-
-
33744489071
-
Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays
-
Jiang R, Mircean C, Shmulevich I, Cogdell D, Jia Y, et al. 2006. Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays. Proteomics 6:2964-71
-
(2006)
Proteomics
, vol.6
, pp. 2964-2971
-
-
Jiang, R.1
Mircean, C.2
Shmulevich, I.3
Cogdell, D.4
Jia, Y.5
-
57
-
-
84859778293
-
MTOR signaling in growth control and disease
-
Laplante M, Sabatini DM. 2012. mTOR signaling in growth control and disease. Cell 149:274-93
-
(2012)
Cell
, vol.149
, pp. 274-293
-
-
Laplante, M.1
Sabatini, D.M.2
-
59
-
-
33750351403
-
Signal transduction: Protein synthesis and oncogenesis meet again
-
Sonenberg N, Pause A. 2006. Signal transduction: Protein synthesis and oncogenesis meet again. Science 314:428-29
-
(2006)
Science
, vol.314
, pp. 428-429
-
-
Sonenberg, N.1
Pause, A.2
-
60
-
-
79955779584
-
MTOR links oncogenic signaling to tumor cell metabolism
-
Yecies JL, Manning BD. 2011. mTOR links oncogenic signaling to tumor cell metabolism. J. Mol. Med. 89:221-28
-
(2011)
J. Mol. Med.
, vol.89
, pp. 221-228
-
-
Yecies, J.L.1
Manning, B.D.2
-
61
-
-
32944457518
-
MTORinhibition induces upstream receptor tyrosine kinase signaling and activates Akt
-
OReilly KE, Rojo F, She QB, Solit D, Mills GB, et al. 2006.mTORinhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66:1500-8
-
(2006)
Cancer Res.
, vol.66
, pp. 1500-1508
-
-
Oreilly, K.E.1
Rojo, F.2
She, Q.B.3
Solit, D.4
Mills, G.B.5
-
62
-
-
42949139481
-
AMPK phosphorylation of raptor mediates a metabolic checkpoint
-
Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, et al. 2008. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 30:214-26
-
(2008)
Mol. Cell
, vol.30
, pp. 214-226
-
-
Gwinn, D.M.1
Shackelford, D.B.2
Egan, D.F.3
Mihaylova, M.M.4
Mery, A.5
-
63
-
-
69149097363
-
The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis
-
Guo D, Hildebrandt IJ, Prins RM, Soto H, Mazzotta MM, et al. 2009. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc. Natl. Acad. Sci. USA 106:12932-37
-
(2009)
Proc. Natl. Acad. Sci. USA
, vol.106
, pp. 12932-12937
-
-
Guo, D.1
Hildebrandt, I.J.2
Prins, R.M.3
Soto, H.4
Mazzotta, M.M.5
-
64
-
-
33846164111
-
Renal-cell carcinoma-molecular pathways and therapies
-
Brugarolas J. 2007. Renal-cell carcinoma-molecular pathways and therapies. N. Engl. J.Med. 356:185-87
-
(2007)
N. Engl. J.Med.
, vol.356
, pp. 185-187
-
-
Brugarolas, J.1
-
65
-
-
2942724235
-
MTOR inhibition reverses Aktdependent prostate intraepithelial neoplasia through regulation of apoptotic andHIF-1-dependent pathways
-
Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, et al. 2004. mTOR inhibition reverses Aktdependent prostate intraepithelial neoplasia through regulation of apoptotic andHIF-1-dependent pathways. Nat. Med. 10:594-601
-
(2004)
Nat. Med.
, vol.10
, pp. 594-601
-
-
Majumder, P.K.1
Febbo, P.G.2
Bikoff, R.3
Berger, R.4
Xue, Q.5
-
66
-
-
77955483125
-
Activation of a metabolic gene regulatory network downstream of mTOR complex 1
-
Duvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, et al. 2010. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 39:171-83
-
(2010)
Mol. Cell
, vol.39
, pp. 171-183
-
-
Duvel, K.1
Yecies, J.L.2
Menon, S.3
Raman, P.4
Lipovsky, A.I.5
-
67
-
-
50049116472
-
SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth
-
Porstmann T, Santos CR, Griffiths B, Cully M, Wu M, et al. 2008. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. 8:224-36
-
(2008)
Cell Metab.
, vol.8
, pp. 224-236
-
-
Porstmann, T.1
Santos, C.R.2
Griffiths, B.3
Cully, M.4
Wu, M.5
-
68
-
-
79961165137
-
MTOR complex 1 regulates lipin 1 localization to control the SREBP pathway
-
Peterson TR, Sengupta SS, Harris TE, Carmack AE, Kang SA, et al. 2011. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell 146:408-20
-
(2011)
Cell
, vol.146
, pp. 408-420
-
-
Peterson, T.R.1
Sengupta, S.S.2
Harris, T.E.3
Carmack, A.E.4
Kang, S.A.5
-
69
-
-
79251587803
-
Phosphorylation ofULK1 (hATG1) by AMP-Activated protein kinase connects energy sensing to mitophagy
-
EganDF, Shackelford DB, Mihaylova MM, Gelino S, Kohnz RA, et al. 2011. Phosphorylation ofULK1 (hATG1) by AMP-Activated protein kinase connects energy sensing to mitophagy. Science 331:456-61
-
(2011)
Science
, vol.331
, pp. 456-461
-
-
Egan, D.F.1
Shackelford, D.B.2
Mihaylova, M.M.3
Gelino, S.4
Kohnz, R.A.5
-
70
-
-
13844312400
-
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
-
Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. 2005. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098-101
-
(2005)
Science
, vol.307
, pp. 1098-1101
-
-
Sarbassov, D.D.1
Guertin, D.A.2
Ali, S.M.3
Sabatini, D.M.4
-
71
-
-
84860816141
-
Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance
-
Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, et al. 2011. Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discov. 1:524-38
-
(2011)
Cancer Discov.
, vol.1
, pp. 524-538
-
-
Tanaka, K.1
Babic, I.2
Nathanson, D.3
Akhavan, D.4
Guo, D.5
-
72
-
-
38849208347
-
Antitumor activity of rapamycin in a Phase i trial for patients with recurrent PTEN-deficient glioblastoma
-
Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, et al. 2008. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 5:e8
-
(2008)
PLoS Med.
, vol.5
, pp. e8
-
-
Cloughesy, T.F.1
Yoshimoto, K.2
Nghiemphu, P.3
Brown, K.4
Dang, J.5
-
73
-
-
56249147509
-
Rapamycin differentially inhibits S6Ks and 4EBP1 tomediate cell-type-specific repression of mRNA translation
-
Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J. 2008. Rapamycin differentially inhibits S6Ks and 4EBP1 tomediate cell-type-specific repression of mRNA translation. Proc. Natl. Acad. Sci. USA 105:17414-19
-
(2008)
Proc. Natl. Acad. Sci. USA
, vol.105
, pp. 17414-17419
-
-
Choo, A.Y.1
Yoon, S.O.2
Kim, S.G.3
Roux, P.P.4
Blenis, J.5
-
75
-
-
84867539301
-
Conditional astroglial rictor overexpression induces malignant glioma in mice
-
Bashir T, Cloninger C, Artinian N, Anderson L, Bernath A, et al. 2012. Conditional astroglial rictor overexpression induces malignant glioma in mice. PLoS ONE 7:e47741
-
(2012)
PLoS ONE
, vol.7
, pp. e47741
-
-
Bashir, T.1
Cloninger, C.2
Artinian, N.3
Anderson, L.4
Bernath, A.5
-
76
-
-
37549048521
-
MTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor
-
Masri J, Bernath A, Martin J, Jo OD, Vartanian R, et al. 2007. mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res. 67:11712-20
-
(2007)
Cancer Res.
, vol.67
, pp. 11712-11720
-
-
Masri, J.1
Bernath, A.2
Martin, J.3
Jo, O.D.4
Vartanian, R.5
-
77
-
-
0032510679
-
Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases
-
Nagane M, Levitzki A, Gazit A, Cavenee WK, Huang HJ. 1998. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc. Natl. Acad. Sci. USA 95:5724-29
-
(1998)
Proc. Natl. Acad. Sci. USA
, vol.95
, pp. 5724-5729
-
-
Nagane, M.1
Levitzki, A.2
Gazit, A.3
Cavenee, W.K.4
Huang, H.J.5
-
78
-
-
78149475478
-
Akt and autophagy cooperate to promote survival of drug-resistant glioma
-
Fan QW, Cheng C, Hackett C, Feldman M, Houseman BT, et al. 2010. Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci. Signal. 3:ra81
-
(2010)
Sci. Signal.
, vol.3
, pp. ra81
-
-
Fan, Q.W.1
Cheng, C.2
Hackett, C.3
Feldman, M.4
Houseman, B.T.5
-
79
-
-
33745316089
-
Identification of a tumour suppressor network opposing nuclear Akt function
-
TrotmanLC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandolfi PP. 2006. Identification of a tumour suppressor network opposing nuclear Akt function. Nature 441:523-27
-
(2006)
Nature
, vol.441
, pp. 523-527
-
-
Trotman, L.C.1
Alimonti, A.2
Scaglioni, P.P.3
Koutcher, J.A.4
Cordon-Cardo, C.5
Pandolfi, P.P.6
-
80
-
-
33747488399
-
PML inhibits HIF-1αtranslation and neoangiogenesis through repression of mTOR
-
Bernardi R, Guernah I, Jin D, Grisendi S, Alimonti A, et al. 2006. PML inhibits HIF-1αtranslation and neoangiogenesis through repression of mTOR. Nature 442:779-85
-
(2006)
Nature
, vol.442
, pp. 779-785
-
-
Bernardi, R.1
Guernah, I.2
Jin, D.3
Grisendi, S.4
Alimonti, A.5
-
81
-
-
84875009534
-
PMLmediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies
-
Iwanami A, Gini B, Zanca C, MatsutaniT, Assuncao A, et al. 2013.PMLmediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies. Proc. Natl. Acad. Sci. USA 110:4339-44
-
(2013)
Proc. Natl. Acad. Sci. USA
, vol.110
, pp. 4339-4344
-
-
Iwanami, A.1
Gini, B.2
Zanca, C.3
Matsutani, T.4
Assuncao, A.5
-
82
-
-
70349653793
-
IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas
-
Nobusawa S, Watanabe T, Kleihues P, Ohgaki H. 2009. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin. Cancer Res. 15:6002-7
-
(2009)
Clin. Cancer Res.
, vol.15
, pp. 6002-6007
-
-
Nobusawa, S.1
Watanabe, T.2
Kleihues, P.3
Ohgaki, H.4
-
83
-
-
60849115270
-
IDH1 and IDH2 mutations in gliomas
-
Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, et al. 2009. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360:765-73
-
(2009)
N. Engl. J. Med.
, vol.360
, pp. 765-773
-
-
Yan, H.1
Parsons, D.W.2
Jin, G.3
McLendon, R.4
Rasheed, B.A.5
-
84
-
-
72049125350
-
Cancer-Associated IDH1mutations produce 2-hydroxyglutarate
-
Dang L, WhiteDW, Gross S, Bennett BD, Bittinger MA, et al. 2009. Cancer-Associated IDH1mutations produce 2-hydroxyglutarate. Nature 462:739-44
-
(2009)
Nature
, vol.462
, pp. 739-744
-
-
Dang, L.1
White, D.W.2
Gross, S.3
Bennett, B.D.4
Bittinger, M.A.5
-
85
-
-
78650019179
-
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation
-
Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, et al. 2010. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18:553-67
-
(2010)
Cancer Cell
, vol.18
, pp. 553-567
-
-
Figueroa, M.E.1
Abdel-Wahab, O.2
Lu, C.3
Ward, P.S.4
Patel, J.5
-
86
-
-
77649305610
-
The common feature of leukemiaassociated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate
-
Ward PS, Patel J, Wise DR, Abdel-WahabO, Bennett BD, et al. 2010. The common feature of leukemiaassociated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17:225-34
-
(2010)
Cancer Cell
, vol.17
, pp. 225-234
-
-
Ward, P.S.1
Patel, J.2
Wise, D.R.3
Abdel-Wahab, O.4
Bennett, B.D.5
-
87
-
-
84862776918
-
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
-
Koivunen P, Lee S, Duncan CG, Lopez G, Lu G, et al. 2012. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 483:484-88
-
(2012)
Nature
, vol.483
, pp. 484-488
-
-
Koivunen, P.1
Lee, S.2
Duncan, C.G.3
Lopez, G.4
Lu, G.5
-
88
-
-
83355163405
-
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin
-
LaiA, Kharbanda S, PopeWB, Tran A, Solis OE, et al. 2011. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J. Clin. Oncol. 9:4482-90
-
(2011)
J. Clin. Oncol.
, vol.9
, pp. 4482-4490
-
-
Lai, A.1
Kharbanda, S.2
Pope, W.B.3
Tran, A.4
Solis, O.E.5
-
89
-
-
84858796262
-
IDH mutation impairs histone demethylation and results in a block to cell differentiation
-
Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, et al. 2012. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483:474-78
-
(2012)
Nature
, vol.483
, pp. 474-478
-
-
Lu, C.1
Ward, P.S.2
Kapoor, G.S.3
Rohle, D.4
Turcan, S.5
-
90
-
-
60949083613
-
The molecular determinants of de novo nucleotide biosynthesis in cancer cells
-
Tong X, Zhao F, Thompson CB. 2009. The molecular determinants of de novo nucleotide biosynthesis in cancer cells. Curr. Opin. Genet. Dev. 19:32-37
-
(2009)
Curr. Opin. Genet. Dev.
, vol.19
, pp. 32-37
-
-
Tong, X.1
Zhao, F.2
Thompson, C.B.3
-
91
-
-
84862016091
-
Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo
-
Marin-Valencia I, Yang C, MashimoT, Cho S, Baek H, et al. 2012. Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab. 15:827-37
-
(2012)
Cell Metab.
, vol.15
, pp. 827-837
-
-
Marin-Valencia, I.1
Yang, C.2
Mashimo, T.3
Cho, S.4
Baek, H.5
-
92
-
-
40749163248
-
TheM2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
-
Christofk HR, VanderHeidenMG, HarrisMH, Ramanathan A, Gerszten RE, et al. 2008. TheM2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452:230-33
-
(2008)
Nature
, vol.452
, pp. 230-233
-
-
Christofk, H.R.1
Vanderheiden, M.G.2
Harris, M.H.3
Ramanathan, A.4
Gerszten, R.E.5
-
93
-
-
40749099894
-
Pyruvate kinase M2 is a phosphotyrosine-binding protein
-
Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC. 2008. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452:181-86
-
(2008)
Nature
, vol.452
, pp. 181-186
-
-
Christofk, H.R.1
Vander Heiden, M.G.2
Wu, N.3
Asara, J.M.4
Cantley, L.C.5
-
94
-
-
66249108601
-
Understanding the Warburg effect: The metabolic requirements of cell proliferation
-
Vander Heiden MG, Cantley LC, Thompson CB. 2009. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029-33
-
(2009)
Science
, vol.324
, pp. 1029-1033
-
-
Vander Heiden, M.G.1
Cantley, L.C.2
Thompson, C.B.3
-
95
-
-
75149150660
-
HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer
-
David CJ, Chen M, Assanah M, Canoll P, Manley JL. 2010. hnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463:364-68
-
(2010)
Nature
, vol.463
, pp. 364-368
-
-
David, C.J.1
Chen, M.2
Assanah, M.3
Canoll, P.4
Manley, J.L.5
-
96
-
-
84856189114
-
Nonmetabolic functions of pyruvate kinase isoform M2 in controlling cell cycle progression and tumorigenesis
-
Lu Z. 2012. Nonmetabolic functions of pyruvate kinase isoform M2 in controlling cell cycle progression and tumorigenesis. Chin. J. Cancer 31:5-7
-
(2012)
Chin. J. Cancer
, vol.31
, pp. 5-7
-
-
Lu, Z.1
-
97
-
-
84870885534
-
EGFR-induced and PKC? Monoubiquitylation- dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis
-
Yang W, Xia Y, Cao Y, Zheng Y, Bu W, et al. 2012. EGFR-induced and PKC? monoubiquitylation- dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis. Mol. Cell 48:771-84
-
(2012)
Mol. Cell
, vol.48
, pp. 771-784
-
-
Yang, W.1
Xia, Y.2
Cao, Y.3
Zheng, Y.4
Bu, W.5
-
98
-
-
82555170271
-
Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation
-
Yang W, Xia Y, Ji H, Zheng Y, Liang J, et al. 2011. Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation. Nature 480:118-22
-
(2011)
Nature
, vol.480
, pp. 118-122
-
-
Yang, W.1
Xia, Y.2
Ji, H.3
Zheng, Y.4
Liang, J.5
-
99
-
-
84865266173
-
PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis
-
Yang W, Xia Y, Hawke D, Li X, Liang J, et al. 2012. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 150:685-96
-
(2012)
Cell
, vol.150
, pp. 685-696
-
-
Yang, W.1
Xia, Y.2
Hawke, D.3
Li, X.4
Liang, J.5
-
100
-
-
84870598190
-
ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect
-
Yang W, Zheng Y, Xia Y, Ji H, Chen X, et al. 2012. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat. Cell Biol. 14:1295-304
-
(2012)
Nat. Cell Biol.
, vol.14
, pp. 1295-1304
-
-
Yang, W.1
Zheng, Y.2
Xia, Y.3
Ji, H.4
Chen, X.5
-
101
-
-
84878800044
-
EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer
-
Babic I, Anderson ES, Tanaka K, Guo D, Masui K, et al. 2013. EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. Cell Metab. 17:1000-8
-
(2013)
Cell Metab.
, vol.17
, pp. 1000-1008
-
-
Babic, I.1
Anderson, E.S.2
Tanaka, K.3
Guo, D.4
Masui, K.5
-
102
-
-
84859752151
-
The music of lipids: How lipid composition orchestrates cellular behaviour
-
Schug ZT, Frezza C, Galbraith LC, Gottlieb E. 2012. The music of lipids: how lipid composition orchestrates cellular behaviour. Acta Oncol. 51:301-10
-
(2012)
Acta Oncol.
, vol.51
, pp. 301-310
-
-
Schug, Z.T.1
Frezza, C.2
Galbraith, L.C.3
Gottlieb, E.4
-
103
-
-
84858604270
-
Metabolic reprogramming: A cancer hallmark even Warburg did not anticipate
-
Ward PS, Thompson CB. 2012. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 21:297-308
-
(2012)
Cancer Cell
, vol.21
, pp. 297-308
-
-
Ward, P.S.1
Thompson, C.B.2
-
104
-
-
77649216053
-
EGFR signaling through an Akt-SREBP- 1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy
-
Guo D, Prins RM, Dang J, Kuga D, Iwanami A, et al. 2009. EGFR signaling through an Akt-SREBP- 1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci. Signal. 2:ra82
-
(2009)
Sci. Signal.
, vol.2
, pp. ra82
-
-
Guo, D.1
Prins, R.M.2
Dang, J.3
Kuga, D.4
Iwanami, A.5
-
105
-
-
0030941803
-
The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor
-
Brown MS, Goldstein JL. 1997. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89:331-40
-
(1997)
Cell
, vol.89
, pp. 331-340
-
-
Brown, M.S.1
Goldstein, J.L.2
-
106
-
-
84877961669
-
Sterol regulatory element binding protein-dependent regulation of lipid synthesis supports cell survival and tumor growth
-
Griffiths B, Lewis CA, Bensaad K, Ros S, Zhang Q, et al. 2013. Sterol regulatory element binding protein-dependent regulation of lipid synthesis supports cell survival and tumor growth. Camcer Metab. 1:3
-
(2013)
Camcer Metab.
, vol.1
, pp. 3
-
-
Griffiths, B.1
Lewis, C.A.2
Bensaad, K.3
Ros, S.4
Zhang, Q.5
-
107
-
-
84877731629
-
An essential requirement for the SCAP/SREBP signaling axis to protect cancer cells from lipotoxicity
-
Williams KJ, Argus JP, Zhu Y, Wilks MQ, Marbois BN, et al. 2013. An essential requirement for the SCAP/SREBP signaling axis to protect cancer cells from lipotoxicity. Cancer Res. 73:2850-62
-
(2013)
Cancer Res.
, vol.73
, pp. 2850-2862
-
-
Williams, K.J.1
Argus, J.P.2
Zhu, Y.3
Wilks, M.Q.4
Marbois, B.N.5
-
108
-
-
84861101004
-
AnLXRagonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway
-
GuoD, Reinitz F, YoussefM, HongC, Nathanson D, et al. 2011. AnLXRagonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov. 1:442-56
-
(2011)
Cancer Discov.
, vol.1
, pp. 442-456
-
-
Guo, D.1
Reinitz, F.2
Youssef, M.3
Hong, C.4
Nathanson, D.5
-
109
-
-
84856004321
-
Single-cell proteomic chip for profiling intracellular signaling pathways in single tumor cells
-
Shi Q, Qin L, Wei W, Geng F, Fan R, et al. 2012. Single-cell proteomic chip for profiling intracellular signaling pathways in single tumor cells. Proc. Natl. Acad. Sci. USA 109:419-24
-
(2012)
Proc. Natl. Acad. Sci. USA
, vol.109
, pp. 419-424
-
-
Shi, Q.1
Qin, L.2
Wei, W.3
Geng, F.4
Fan, R.5
-
112
-
-
0036737914
-
Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro
-
Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD, Steindler DA. 2002. Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 39:193-206
-
(2002)
Glia
, vol.39
, pp. 193-206
-
-
Ignatova, T.N.1
Kukekov, V.G.2
Laywell, E.D.3
Suslov, O.N.4
Vrionis, F.D.5
Steindler, D.A.6
-
113
-
-
9244241576
-
Identification of human brain tumour initiating cells
-
Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, et al. 2004. Identification of human brain tumour initiating cells. Nature 432:396-401
-
(2004)
Nature
, vol.432
, pp. 396-401
-
-
Singh, S.K.1
Hawkins, C.2
Clarke, I.D.3
Squire, J.A.4
Bayani, J.5
-
114
-
-
0344735881
-
Cancerous stem cells can arise from pediatric brain tumors
-
Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, et al. 2003. Cancerous stem cells can arise from pediatric brain tumors. Proc. Natl. Acad. Sci. USA 100:15178-83
-
(2003)
Proc. Natl. Acad. Sci. USA
, vol.100
, pp. 15178-15183
-
-
Hemmati, H.D.1
Nakano, I.2
Lazareff, J.A.3
Masterman-Smith, M.4
Geschwind, D.H.5
-
115
-
-
77956245743
-
Integrinα6 regulates glioblastoma stem cells
-
Lathia JD, Gallagher J, Heddleston JM, Wang J, EylerCE, et al. 2010. Integrinα6 regulates glioblastoma stem cells. Cell Stem Cell 6:421-32
-
(2010)
Cell Stem Cell
, vol.6
, pp. 421-432
-
-
Lathia, J.D.1
Gallagher, J.2
Heddleston, J.M.3
Wang, J.4
Eyler, C.E.5
-
116
-
-
65349115320
-
SSEA-1 is an enrichment marker for tumorinitiating cells in human glioblastoma
-
Son MJ, Woolard K, Nam DH, Lee J, Fine HA. 2009. SSEA-1 is an enrichment marker for tumorinitiating cells in human glioblastoma. Cell Stem Cell 4:440-52
-
(2009)
Cell Stem Cell
, vol.4
, pp. 440-452
-
-
Son, M.J.1
Woolard, K.2
Nam, D.H.3
Lee, J.4
Fine, H.A.5
-
117
-
-
84861789402
-
Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity
-
Kim Y, Kim E, Wu Q, Guryanova O, Hitomi M, et al. 2012. Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity. Genes Dev. 26:1247-62
-
(2012)
Genes Dev.
, vol.26
, pp. 1247-1262
-
-
Kim, Y.1
Kim, E.2
Wu, Q.3
Guryanova, O.4
Hitomi, M.5
-
118
-
-
79959969874
-
Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase 2
-
Eyler CE, Wu Q, Yan K, MacSwords JM, Chandler-Militello D, et al. 2011. Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase 2. Cell 146:53-66
-
(2011)
Cell
, vol.146
, pp. 53-66
-
-
Eyler, C.E.1
Wu, Q.2
Yan, K.3
Macswords, J.M.4
Chandler-Militello, D.5
-
119
-
-
75349091751
-
Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells
-
CharlesN, OzawaT, SquatritoM, Bleau AM, BrennanCW, et al. 2010. Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell 6:141-52
-
(2010)
Cell Stem Cell
, vol.6
, pp. 141-152
-
-
Charles, N.1
Ozawa, T.2
Squatrito, M.3
Bleau, A.M.4
Brennan, C.W.5
-
120
-
-
80053058993
-
Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells
-
Lathia JD, Gallagher J, Myers JT, Li M, Vasanji A, et al. 2011. Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells. PLoS ONE 6:e24807
-
(2011)
PLoS ONE
, vol.6
, pp. e24807
-
-
Lathia, J.D.1
Gallagher, J.2
Myers, J.T.3
Li, M.4
Vasanji, A.5
-
121
-
-
33845317573
-
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
-
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, et al. 2006. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756-60
-
(2006)
Nature
, vol.444
, pp. 756-760
-
-
Bao, S.1
Wu, Q.2
McLendon, R.E.3
Hao, Y.4
Shi, Q.5
-
122
-
-
84865203983
-
A restricted cell population propagates glioblastoma growth after chemotherapy
-
Chen J, Li Y, Yu TS, McKay RM, Burns DK, et al. 2012. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488:522-26
-
(2012)
Nature
, vol.488
, pp. 522-526
-
-
Chen, J.1
Li, Y.2
Yu, T.S.3
McKay, R.M.4
Burns, D.K.5
-
123
-
-
33846029123
-
A perivascular niche for brain tumor stem cells
-
Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, et al. 2007. A perivascular niche for brain tumor stem cells. Cancer Cell 11:69-82
-
(2007)
Cancer Cell
, vol.11
, pp. 69-82
-
-
Calabrese, C.1
Poppleton, H.2
Kocak, M.3
Hogg, T.L.4
Fuller, C.5
-
124
-
-
79955031521
-
Seeing is believing: Are cancer stem cells the Loch Ness monster of tumor biology?
-
Lathia JD, Venere M, Rao MS, Rich JN. 2011. Seeing is believing: Are cancer stem cells the Loch Ness monster of tumor biology? Stem Cell Rev. 7:227-37
-
(2011)
Stem Cell Rev.
, vol.7
, pp. 227-237
-
-
Lathia, J.D.1
Venere, M.2
Rao, M.S.3
Rich, J.N.4
-
125
-
-
19044397160
-
Epidermal growth factor receptor and INK4A/ARF: Convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis
-
Bachoo RM, Maher EA, Ligon KL, Sharpless NE, Chan SS, et al. 2002. Epidermal growth factor receptor and INK4A/ARF: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 1:269-77
-
(2002)
Cancer Cell
, vol.1
, pp. 269-277
-
-
Bachoo, R.M.1
Maher, E.A.2
Ligon, K.L.3
Sharpless, N.E.4
Chan, S.S.5
-
126
-
-
23644443053
-
Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma
-
Zhu Y, Guignard F, Zhao D, Liu L, Burns DK, et al. 2005. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 8:119-30
-
(2005)
Cancer Cell
, vol.8
, pp. 119-130
-
-
Zhu, Y.1
Guignard, F.2
Zhao, D.3
Liu, L.4
Burns, D.K.5
-
127
-
-
57849109837
-
Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model
-
Alcantara Llaguno S, Chen J, Kwon CH, Jackson EL, Li Y, et al. 2009. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 15:45-56
-
(2009)
Cancer Cell
, vol.15
, pp. 45-56
-
-
Alcantara Llaguno, S.1
Chen, J.2
Kwon, C.H.3
Jackson, E.L.4
Li, Y.5
-
128
-
-
79953766940
-
Tumour evolution inferred by single-cell sequencing
-
NavinN, Kendall J, Troge J, Andrews P, Rodgers L, et al. 2011. Tumour evolution inferred by single-cell sequencing. Nature 472:90-94
-
(2011)
Nature
, vol.472
, pp. 90-94
-
-
Navin, N.1
Kendall, J.2
Troge, J.3
Andrews, P.4
Rodgers, L.5
-
129
-
-
84863393080
-
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing
-
GerlingerM, Rowan AJ, Horswell S, Larkin J, Endesfelder D, et al. 2012. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366:883-92
-
(2012)
N. Engl. J. Med.
, vol.366
, pp. 883-892
-
-
Gerlinger, M.1
Rowan, A.J.2
Horswell, S.3
Larkin, J.4
Endesfelder, D.5
-
130
-
-
84874598318
-
Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics
-
Sottoriva A, Spiteri I, Piccirillo SG, Touloumis A, Collins VP, et al. 2013. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc. Natl. Acad. Sci. USA 110:4009-14
-
(2013)
Proc. Natl. Acad. Sci. USA
, vol.110
, pp. 4009-4014
-
-
Sottoriva, A.1
Spiteri, I.2
Piccirillo, S.G.3
Touloumis, A.4
Collins, V.P.5
-
131
-
-
84856013431
-
Clonal evolution in cancer
-
Greaves M, Maley CC. 2012. Clonal evolution in cancer. Nature 481:306-13
-
(2012)
Nature
, vol.481
, pp. 306-313
-
-
Greaves, M.1
Maley, C.C.2
-
132
-
-
66249136447
-
Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis
-
Spencer SL, Gaudet S, Albeck JG, Burke JM, Sorger PK. 2009. Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature 459:428-32
-
(2009)
Nature
, vol.459
, pp. 428-432
-
-
Spencer, S.L.1
Gaudet, S.2
Albeck, J.G.3
Burke, J.M.4
Sorger, P.K.5
-
133
-
-
77955911497
-
Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma
-
Inda MM, Bonavia R, Mukasa A, Narita Y, Sah DW, et al. 2010. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev. 24:1731-45
-
(2010)
Genes Dev.
, vol.24
, pp. 1731-1745
-
-
Inda, M.M.1
Bonavia, R.2
Mukasa, A.3
Narita, Y.4
Sah, D.W.5
-
134
-
-
84864285794
-
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
-
StraussmanR, MorikawaT, SheeK, Barzily-RokniM, Qian ZR, et al. 2012. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487:500-4
-
(2012)
Nature
, vol.487
, pp. 500-504
-
-
Straussman, R.1
Morikawa, T.2
Shee, K.3
Barzily-Rokni, M.4
Qian, Z.R.5
-
135
-
-
84857666591
-
Astrocyte-specific expression patterns associated with the PDGF-induced glioma microenvironment
-
Katz AM, Amankulor NM, Pitter K, Helmy K, Squatrito M, Holland EC. 2012. Astrocyte-specific expression patterns associated with the PDGF-induced glioma microenvironment. PLoS ONE 7:e32453
-
(2012)
PLoS ONE
, vol.7
, pp. e32453
-
-
Katz, A.M.1
Amankulor, N.M.2
Pitter, K.3
Helmy, K.4
Squatrito, M.5
Holland, E.C.6
-
136
-
-
84871949179
-
Laminin α2 enables glioblastoma stem cell growth
-
Lathia JD, Li M, Hall PE, Gallagher J, Hales JS, et al. 2012. Laminin α2 enables glioblastoma stem cell growth. Ann. Neurol. 72:766-78
-
(2012)
Ann. Neurol.
, vol.72
, pp. 766-778
-
-
Lathia, J.D.1
Li, M.2
Hall, P.E.3
Gallagher, J.4
Hales, J.S.5
-
137
-
-
84866510711
-
Mechanisms of glioma-Associated neovascularization
-
Hardee ME, Zagzag D. 2012. Mechanisms of glioma-Associated neovascularization. Am. J. Pathol. 181:1126-41
-
(2012)
Am. J. Pathol.
, vol.181
, pp. 1126-1141
-
-
Hardee, M.E.1
Zagzag, D.2
-
138
-
-
78650153633
-
Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells
-
Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, et al. 2010. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468:824-28
-
(2010)
Nature
, vol.468
, pp. 824-828
-
-
Ricci-Vitiani, L.1
Pallini, R.2
Biffoni, M.3
Todaro, M.4
Invernici, G.5
-
139
-
-
78650098659
-
Glioblastoma stem-like cells give rise to tumour endothelium
-
Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, et al. 2010. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468:829-33
-
(2010)
Nature
, vol.468
, pp. 829-833
-
-
Wang, R.1
Chadalavada, K.2
Wilshire, J.3
Kowalik, U.4
Hovinga, K.E.5
-
140
-
-
79952721477
-
Transdifferentiation of glioblastoma cells into vascular endothelial cells
-
Soda Y, Marumoto T, Friedmann-Morvinski D, Soda M, Liu F, et al. 2011. Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc. Natl. Acad. Sci. USA 108:4274-80
-
(2011)
Proc. Natl. Acad. Sci. USA
, vol.108
, pp. 4274-4280
-
-
Soda, Y.1
Marumoto, T.2
Friedmann-Morvinski, D.3
Soda, M.4
Liu, F.5
-
141
-
-
84875755046
-
Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth
-
Cheng L, Huang Z, Zhu W, Wu Q, Donnola S, et al. 2013. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 153:139-52
-
(2013)
Cell
, vol.153
, pp. 139-152
-
-
Cheng, L.1
Huang, Z.2
Zhu, W.3
Wu, Q.4
Donnola, S.5
-
142
-
-
59949083263
-
Phase II trial of single-Agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma
-
Kreisl TN, Kim L, Moore K, Duic P, Royce C, et al. 2009. Phase II trial of single-Agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 27:740-45
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 740-745
-
-
Kreisl, T.N.1
Kim, L.2
Moore, K.3
Duic, P.4
Royce, C.5
-
143
-
-
70350461699
-
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma
-
Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, et al. 2009. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27:4733-40
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 4733-4740
-
-
Friedman, H.S.1
Prados, M.D.2
Wen, P.Y.3
Mikkelsen, T.4
Schiff, D.5
-
144
-
-
84871960565
-
Standards of care for treatment of recurrent glioblastoma: Are we there yet?
-
WellerM, CloughesyTF, Perry JR, Wick W. 2013. Standards of care for treatment of recurrent glioblastoma: Are we there yet? Neuro-Oncology 15:4-27
-
(2013)
Neuro-Oncology
, vol.15
, pp. 4-27
-
-
Weller, M.1
Cloughesy, T.F.2
Perry, J.R.3
Wick, W.4
-
145
-
-
67650075305
-
Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment
-
Pope WB, Kim HJ, Huo J, Alger J, Brown MS, et al. 2009. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 252:182-89
-
(2009)
Radiology
, vol.252
, pp. 182-189
-
-
Pope, W.B.1
Kim, H.J.2
Huo, J.3
Alger, J.4
Brown, M.S.5
-
146
-
-
80755189369
-
Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab
-
Ellingson BM, Cloughesy TF, Lai A, Mischel PS, Nghiemphu PL, et al. 2011. Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. Neuro-Oncology 13:1151-61
-
(2011)
Neuro-Oncology
, vol.13
, pp. 1151-1161
-
-
Ellingson, B.M.1
Cloughesy, T.F.2
Lai, A.3
Mischel, P.S.4
Nghiemphu, P.L.5
-
147
-
-
84863754907
-
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex
-
Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, et al. 2012. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 22:21-35
-
(2012)
Cancer Cell
, vol.22
, pp. 21-35
-
-
Lu, K.V.1
Chang, J.P.2
Parachoniak, C.A.3
Pandika, M.M.4
Aghi, M.K.5
-
148
-
-
78651408563
-
Glioblastoma recurrence after cediranib therapy in patients: Lack of "rebound" revascularization as mode of escape
-
di Tomaso E, Snuderl M, Kamoun WS, Duda DG, Auluck PK, et al. 2011. Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res. 71:19-28
-
(2011)
Cancer Res.
, vol.71
, pp. 19-28
-
-
Di Tomaso, E.1
Snuderl, M.2
Kamoun, W.S.3
Duda, D.G.4
Auluck, P.K.5
-
149
-
-
68049093213
-
Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy
-
Lucio-Eterovic AK, Piao Y, de Groot JF. 2009. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin. Cancer Res. 15:4589-99
-
(2009)
Clin. Cancer Res.
, vol.15
, pp. 4589-4599
-
-
Lucio-Eterovic, A.K.1
Piao, Y.2
De Groot, J.F.3
-
150
-
-
79957927593
-
Genetic modeling of gliomas in mice: New tools to tackle old problems
-
Hambardzumyan D, Parada LF, Holland EC, Charest A. 2011. Genetic modeling of gliomas in mice: new tools to tackle old problems. Glia 59:1155-68
-
(2011)
Glia
, vol.59
, pp. 1155-1168
-
-
Hambardzumyan, D.1
Parada, L.F.2
Holland, E.C.3
Charest, A.4
-
151
-
-
84856029482
-
Mouse models to interrogate the implications of the differentiation status in the ontogeny of gliomas
-
Munoz DM, Guha A. 2011. Mouse models to interrogate the implications of the differentiation status in the ontogeny of gliomas. Oncotarget 2:590-98
-
(2011)
Oncotarget
, vol.2
, pp. 590-598
-
-
Munoz, D.M.1
Guha, A.2
-
152
-
-
62449252775
-
Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis
-
Zhu H, Acquaviva J, Ramachandran P, Boskovitz A, Woolfenden S, et al. 2009. Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc. Natl. Acad. Sci. USA 106:2712-16
-
(2009)
Proc. Natl. Acad. Sci. USA
, vol.106
, pp. 2712-2716
-
-
Zhu, H.1
Acquaviva, J.2
Ramachandran, P.3
Boskovitz, A.4
Woolfenden, S.5
-
153
-
-
0034020459
-
Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice
-
Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN. 2000. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat. Genet. 25:55-57
-
(2000)
Nat. Genet.
, vol.25
, pp. 55-57
-
-
Holland, E.C.1
Celestino, J.2
Dai, C.3
Schaefer, L.4
Sawaya, R.E.5
Fuller, G.N.6
-
154
-
-
58149330085
-
Development of a novel mouse glioma model using lentiviral vectors
-
Marumoto T, Tashiro A, Friedmann-Morvinski D, Scadeng M, Soda Y, et al. 2009. Development of a novel mouse glioma model using lentiviral vectors. Nat. Med. 15:110-16
-
(2009)
Nat. Med.
, vol.15
, pp. 110-116
-
-
Marumoto, T.1
Tashiro, A.2
Friedmann-Morvinski, D.3
Scadeng, M.4
Soda, Y.5
-
155
-
-
34147184365
-
Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel
-
Sarkaria JN, Yang L, Grogan PT, Kitange GJ, Carlson BL, et al. 2007. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol. Cancer Ther. 6:1167-74
-
(2007)
Mol. Cancer Ther.
, vol.6
, pp. 1167-1174
-
-
Sarkaria, J.N.1
Yang, L.2
Grogan, P.T.3
Kitange, G.J.4
Carlson, B.L.5
-
156
-
-
84873110988
-
Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ
-
Joo KM, Kim J, Jin J, Kim M, Seol HJ, et al. 2013. Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ. Cell Rep. 3:260-73
-
(2013)
Cell Rep.
, vol.3
, pp. 260-273
-
-
Joo, K.M.1
Kim, J.2
Jin, J.3
Kim, M.4
Seol, H.J.5
-
157
-
-
77957814624
-
Cellular and vaccine therapeutic approaches for gliomas
-
Hickey MJ, Malone CC, Erickson KL, Jadus MR, Prins RM, et al. 2010. Cellular and vaccine therapeutic approaches for gliomas. J. Transl. Med. 8:100
-
(2010)
J. Transl. Med.
, vol.8
, pp. 100
-
-
Hickey, M.J.1
Malone, C.C.2
Erickson, K.L.3
Jadus, M.R.4
Prins, R.M.5
-
159
-
-
84866767773
-
Decisionmaking and management of gliomas: Practical considerations
-
Hottinger AF, Homicsko K, Negretti L, Lhermitte B, Stupp R. 2012. Decisionmaking and management of gliomas: practical considerations. Ann. Oncol. 23(Suppl. 10):33-40
-
(2012)
Ann. Oncol.
, vol.23
, Issue.SUPPL. 10
, pp. 33-40
-
-
Hottinger, A.F.1
Homicsko, K.2
Negretti, L.3
Lhermitte, B.4
Stupp, R.5
-
160
-
-
84856728163
-
Individualized targeted therapy for glioblastoma: Fact or fiction?
-
Weller M, Stupp R, Hegi M, Wick W. 2012. Individualized targeted therapy for glioblastoma: fact or fiction? Cancer J. 18:40-44
-
(2012)
Cancer J.
, vol.18
, pp. 40-44
-
-
Weller, M.1
Stupp, R.2
Hegi, M.3
Wick, W.4
-
161
-
-
78650029376
-
The use of global profiling in biomarker development for gliomas
-
Sulman EP, Aldape K. 2011. The use of global profiling in biomarker development for gliomas. Brain Pathol. 21:88-95
-
(2011)
Brain Pathol.
, vol.21
, pp. 88-95
-
-
Sulman, E.P.1
Aldape, K.2
|